Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Spineart USA, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Spineart USA, Inc.

Regulatory records
3
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 3 FDA records to the applicant name Spineart USA, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 10, 2026 to Sep 22, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MJO appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250042, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 23332 Mill Creek Dr., Suite 150, Laguna Hills, CA, 92653. Recorded on P250042/S002, decision dated Sep 22, 2026.

Changes described in PMA records

P250042/S002: BAGUERAC Cervical Disc Prosthesis

Spineart USA, Inc. submitted a post-approval study protocol for the BAGUERA C Cervical Disc Prosthesis under supplement S002 to PMA P250042. The FDA database records the decision as APPR and lists the supplement type as Normal 180 Day Track No User Fee, with the supplement reason given as Postapproval Study Protocol.

The statement indicates the protocol was submitted to comply with conditions of approval in the approval order for P250042. The record does not include the protocol contents, study endpoints, enrollment targets, or any safety or effectiveness findings. The submission of a protocol is distinct from evidence that the device is safe or effective.

FDA approval-order wording

requested approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250042

Sep 22, 2026 · Normal 180 Day Track No User Fee

P250042/S001: BAGUERAC Cervical Disc Prosthesis

FDA’s recorded scope: addition of a new raw material supplier, Industriekeramik Hochrhein (IKH), for titanium powder used in the plasma spray coating of BAGUERA C inferior and superior endplates

Aug 27, 2026 · 30-Day Notice

P250042: BAGUERAC Cervical Disc Prosthesis

The FDA approved the BAGUERA® C Cervical Disc Prosthesis from Spineart USA, Inc. on August 10, 2026. The approval covers reconstruction of the disc at one or two contiguous levels from C3-C7 after single-level or two-contiguous-level discectomy in skeletally mature patients with intractable radiculopathy or myelopathy.

Eligible conditions include herniated nucleus pulposus, spondylosis with osteophytes, or visible loss of disc height confirmed by imaging. Patients must have failed at least six weeks of non-operative treatment or have progressive symptoms. The device is implanted via an open anterior approach.

FDA approval-order wording

The BAGUERA C Cervical Disc Prosthesis is indicated for use in skeletally mature patients for reconstruction of the disc at one or two contiguous levels from C3-C7 following single-level or two-contiguous-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to a single-level or two-contiguous-level abnormality localized to the level of the disc space and manifested by at least one of the following conditions confirmed by radiographic imaging (e.g., X-rays, computed tomography (CT), magnetic resonance imaging (MRI)): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. Patients receiving the BAGUERA C Cervical Disc Prosthesis should have failed at least six weeks of non-operative treatment or have the presence of progressive symptoms (e.g., numbness or tingling) prior to implantation. The BAGUERA C Cervical Disc Prosthesis is implanted via an open anterior approach.

Aug 10, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Spineart USA, Inc.PMA supplementSep 22, 2026FDA
Spineart USA, Inc.PMA supplementAug 27, 2026FDA
Spineart USA, Inc.PMA approvalAug 10, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.